title: Monoclonal Antibodies.
abstract: Use of monoclonal antibodies (mAbs) has revolutionized cancer therapy. Approaches targeting specific cellular targets on the malignant cells and in tumor microenvironment have been proved to be successful in hematologic malignancies, including cutaneous lymphomas. mAb-based therapy for cutaneous T-cell lymphoma has demonstrated high response rates and a favorable toxicity profile in clinical trials. Several antibodies and antibody-based conjugates are approved for use in clinical practice, and many more are in ongoing and planned clinical trials. In addition, these safe and effective drugs can be used as pillars for sequential therapies in a rational stepwise manner.
authors.affiliation: Comprehensive Cutaneous Oncology Center, Department of Dermatology, Columbia University, 161 Fort Washington Avenue, 12th floor, New York, NY 10032, USA. Electronic address: geskinlj@gmail.com.
authors.forename: Larisa J
authors.initials: LJ
authors.lastname: Geskin
mesh_terms: D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000145:classification / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols; D000079963:Brentuximab Vedotin; D002986:Clinical Trials as Topic; D004167:Diphtheria Toxin / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D018796:Immunoconjugates / Q000009:adverse effects / Q000627:therapeutic use; D007376:Interleukin-2 / Q000009:adverse effects / Q000627:therapeutic use; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy*; D058990:Molecular Targeted Therapy; D011993:Recombinant Fusion Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D004167:Diphtheria Toxin; D018796:Immunoconjugates; D007376:Interleukin-2; D011993:Recombinant Fusion Proteins; C078456:denileukin diftitox; D000074323:Alemtuzumab; D000079963:Brentuximab Vedotin
keywords: Antibody conjugates; Antibody therapy; Clinical trials; Cutaneous lymphoma